$CBRSBullishLow

Comparing Cerebras Systems (NASDAQ:CBRS) & Aeluma (NASDAQ:ALMU)

MarketBeat.com compares Cerebras Systems (CBRS) and Aeluma (ALMU). It reports Aeluma has a consensus price target of $25.33 (about 4% upside) and a stronger consensus rating. The article also states Cerebras has higher revenue and earnings, while profitability metrics are compared via net margin and returns on equity/assets.

6/10
Low
Bullish
No event date (earnings/contract/regulatory decision) is provided; impact is mainly from analyst-target framing.
Leans slightly positive for both names via analyst favorability (ALMU) and hyperscaler deployment narrative (CBRS).

Read-through is modestly bullish for CBRS on potential distribution via AWS, but the piece is largely comparative/valuation-focused rather than a new catalyst.

The article profiles Cerebras’ wafer-scale AI inference claims and cites a binding AWS term sheet to deploy its chips in hyperscaler data centers.

Near-term price reaction likely limited; any upside would depend on how investors weigh the AWS deployment claim versus valuation and execution risk.

Background

The article compares Cerebras Systems (CBRS) and Aeluma (ALMU) across earnings/valuation/profitability and includes a narrative on Cerebras’ wafer-scale AI inference speed and Aeluma’s analyst price target.

Why it matters

Trading relevance is primarily sentiment/positioning from analyst-target framing (ALMU) and a hyperscaler deployment narrative (CBRS), rather than a discrete new corporate action.

Market relevance

Investors may use the article to adjust relative positioning between AI infrastructure (CBRS) and compound semiconductor exposure (ALMU), but it lacks a clear new catalyst.

Market effects

Highlights investor attention on AI infrastructure (CBRS) and compound semiconductor/optoelectronics exposure (ALMU), but without new sector-wide policy or demand shock.

Limited; both companies are US-based and the article does not cite regional procurement or regulatory changes.

Limited; the AI infrastructure TAM figures are cited but not tied to a new global order, trial, or regulation.

Alternative perspectives

The piece is a comparison article with heavy marketing language and no verifiable new financial datapoints; analyst targets can lag fundamentals and may not drive sustained repricing.

Execution risk (CBRS wafer-scale yield/cost and customer ramp) and potential cyclicality/competition in compound semiconductors (ALMU) are not quantified; valuation tables are referenced but not numerically detailed here.

Key entities

  • Cerebras Systems

    Wafer-scale AI inference provider; article cites OpenAI selection and an AWS binding term sheet to deploy in AWS data centers.

  • Aeluma

    Optoelectronic/electronic devices company; article cites a consensus price target of $25.33 and relative analyst favorability.

  • Amazon Web Services

    Cited as signing a binding term sheet with Cerebras for deployment in its own data centers.

  • OpenAI

    Cited as selecting Cerebras as a fast inference solution for Codex-Spark users.

Related articles

$CBRSMed

Cerebras shares jump as Wall Street initiates coverage with bullish calls

Cerebras Systems (NASDAQ:CBRS) shares rose about 23% after the post–quiet period coverage began for the AI chip designer. At least nine brokerages initiated, with price targets ranging from $250 (Morgan Stanley) to $300 (Mizuho/UBS/Rosenblatt) and $270 (Wedbush). UBS cited fast inference demand, OpenAI pre-payment shipments, and AWS collaborations, setting a $300 target based on 10x EV/Sales of 2029E $11.2B revenue.

$SNDKMedAI 8/10

These 2 AI Stocks Dominated Headlines in May. How to Play Them in June.

In May, Wall Street rated SanDisk “Strong Buy” overall, with 18 of 22 analysts bullish; one “Moderate Buy” and three “Hold.” The stock has surpassed its mean target, while the Street-high estimate is $3,250 (about 82% upside). Cerebras’ IPO shares rose ~68% on May 14 to $311.07, then fell 24%; market cap is ~$47B. Cerebras reported revenue up 76% YoY to $510M and net income of $237.8M in 2025.

$ALMUMed

The Speed of Light: 5 Stocks Powering AI’s Optical Future

MarketBeat highlights NVIDIA’s broader photonics investment and says the global photonics market is about $1.25T, growing mid-single digits through the next decade, with silicon photonics rising ~30% annually. It profiles Aeluma (NASDAQ: ALMU), citing quantum-dot lasers and a manufacturing method that grows optical-quality substrate on silicon. The article notes Aeluma is pre-revenue, seeks data-center/defense partnerships for design wins and prototype certifications, and targets production and

$CRWVLow

3 AI Stocks Born From Recent IPOs That Could Be Bigger Than Their Hype

The article highlights three AI-focused public companies from recent listings: CoreWeave (CRWV), Cerebras (CBRS), and Nebius Group (NBIS). CoreWeave IPO’d March 28, 2025 at $40; it reported Q1 2026 revenue of $2.1B (+112% YoY) and forecasts $12B–$13B for 2026, with $99.4B backlog, but carries $35.1B debt. Cerebras debuted May 14, 2025 at $185; 2025 revenue was $510M (+76% YoY) and it trades at ~100x trailing sales. Nebius Group reported Q1 2026 revenue of $399M (+684% YoY) and guided $3.0B–$3.4B

$CBRSLow

The Cerebras IPO Just Showed Us Exactly What’s Coming With SpaceX

The article argues that AI IPOs may follow a “lockup trap” structure that enables early insider selling. It cites Figma’s IPO: priced at $33, opened at $115, and a performance-based lockup release triggered on Day 1; insiders sold at about $80 within 36 days and the stock later fell to $22. It says Cerebras priced at $185 and opened at $350, and claims SpaceX, Anthropic, and OpenAI may use similar setups.

$NVDALow

Better AI Inference Stock to Own: Nvidia or Cerebras?

The article argues that AI inference may become a larger market than LLM training and compares Nvidia (NVDA) with Cerebras (CBRS). It says Nvidia’s $20 billion “acquisition” of Groq gives it inference-focused LPUs integrated into CUDA and rack systems with GPUs using HBM for prefill and LPUs for decode. It says Cerebras uses wafer-scale SRAM chips sold as CS-3 systems, claiming 15x faster inference but facing yield, cooling, and high valuation concerns.